Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VCYT
Strong BuyPremium GrowerFLAGVeracyte, Inc. · Healthcare · United States · $3.5B · Avg Vol: $59M/d
Veracyte has strong quality Q73 and momentum M85, but value at V24 is well below the calibrated floor, so stage one fails. Insider selling of 0.25% is separately adverse.
COMPANY DESCRIPTION
Veracyte, Inc. is a global diagnostics company focused on genomic tests for difficult-to-diagnose diseases, particularly in oncology, pulmonology, and endocrinology. Its competitive moat lies in its proprietary genomic platforms and clinically validated tests that provide actionable insights, reducing the need for invasive procedures. Veracyte is a specialized diagnostics leader, benefiting from strong intellectual property and a growing portfolio of revenue-generating precision medicine tests.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 296.5M | 361.1M | 445.8M | 517.1M | 20.4% | 561.9M | 593.8M | 661.1M | 13.1% |
| EPS | -0.51 | -1.02 | 0.32 | 0.84 | 162.5% | 1.40 | 0.90 | 0.92 | 4.7% |
| Shares | 72.0M | 73.3M | 77.8M | 79.4M | +10.3% | 80.4M | — | — | — |
| Debt | 14.7M | 12.6M | 50.7M | 39.7M | 39.1% | 40.1M | — | — | — |
| Equity | 1.1B | 1.0B | 1.2B | 1.3B | 6.8% | — | — | — | — |
| Op CF | 7.5M | 44.2M | 75.1M | 136.3M | 162.5% | 178.4M | — | — | — |
| Inv CF | -29.4M | 15.1M | -56.3M | -9.2M | — | — | — | — | — |
| Fin CF | 3.5M | 2.8M | 4.9M | -4.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VCYT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VCYT | Veracyte, Inc.(you) | $3.5B | 80 | Strong Buy |
| SHC | Sotera Health Company | $5.5B | 81 | Strong Buy |
| CDNA | CareDx, Inc. | $2.6B | 75 | Buy |
| BLLN | BillionToOne, Inc. | $4.4B | 61 | Hold |
| MEDP | Medpace Holdings, Inc. | $16.8B | 80 | Strong Buy |
| NEO | NeoGenomics, Inc. | $2.3B | 47 | Hold |
| DGX | Quest Diagnostics Incorporated | $26.8B | 82 | Strong Buy |
| RVTY | Revvity, Inc. | $14.4B | 64 | Hold |
| LH | Labcorp Holdings Inc. | $27.2B | 83 | Strong Buy |
| ADPT | Adaptive Biotechnologies Corporation | $4.0B | 38 | Hold |
Peer medians: ROE -30.7% · P/E 26.9x · Gross margin 58.1%